Recent genome-wide association studies (GWAS) have mapped many loci associated with complex traits and diseases. Although the relative risks conferred by GWAS loci are often small, the high frequency of some alleles can nonetheless account for a substantial health burden in human populations 1 . For example, SNPs linked to GDF5, which encodes growth differentiation factor 5, are among the best-replicated risk factors for adult-onset osteoarthritis 2 . These alleles increase osteoarthritis risk for specific joints by ~1.2-to 1.8-fold 3, 4 and are also linked to lumbardisk degeneration 5 , hip dysplasia 6 , Achilles tendonopathies 7 , and meniscus tears 8 . Interestingly, risk variants are present at high frequencies in many populations 3, 9 . Although the relative risk due to GDF5 variants may be moderate, their high prevalence contributes a substantial fraction of osteoarthritis risk in many human populations 10 .
Recent genome-wide association studies (GWAS) have mapped many loci associated with complex traits and diseases. Although the relative risks conferred by GWAS loci are often small, the high frequency of some alleles can nonetheless account for a substantial health burden in human populations 1 . For example, SNPs linked to GDF5, which encodes growth differentiation factor 5, are among the best-replicated risk factors for adult-onset osteoarthritis 2 . These alleles increase osteoarthritis risk for specific joints by ~1.2-to 1.8-fold 3, 4 and are also linked to lumbardisk degeneration 5 , hip dysplasia 6 , Achilles tendonopathies 7 , and meniscus tears 8 . Interestingly, risk variants are present at high frequencies in many populations 3, 9 . Although the relative risk due to GDF5 variants may be moderate, their high prevalence contributes a substantial fraction of osteoarthritis risk in many human populations 10 .
High-frequency GDF5 risk alleles show multiple molecular signatures of positive selection during recent human evolution [11] [12] [13] [14] .
Although the causal basis of selection is still unknown, advantageous changes have presumably occurred at one or more body sites influenced by GDF5 activity.
Previous studies have identified multiple structures controlled by GDF5. In mice, Gdf5-null mutations cause shorter feet and limbs; missing joints in digits, wrists, and ankles; altered tendons; missing knee ligaments; and an increased risk of osteoarthritis [15] [16] [17] [18] [19] . Likewise, human GDF5 mutations cause short stature; short digits; joint dislocations or fusions; and hip-and knee-joint dysplasia often concurrent with osteoarthritis [20] [21] [22] [23] .
Interestingly, two common SNPs in the 5′ untranslated region (5′ UTR) of the human gene (rs143383 and rs143384) are associated with a 1.3-to 1.8-fold increased risk of osteoarthritis in Japan and China 3 . Functional studies have shown that T alleles at these SNPs decrease reporter-gene expression in cultured articular cells 3 and are associated with decreased GDF5 transcript levels in the articular cartilage of people with osteoarthritis 24 . Both 5′-UTR variants are also associated with height variation in humans 9, [25] [26] [27] [28] [29] . Homozygosity for T alleles decreases height by approximately 1 cm (ref. 9 ), one of the largest effects identified for GWAS height loci 30 . The decreased height, and increased osteoarthritis risk, may be due to the 5′-UTR mutations or to other linked variants 9 .
Despite high interest in GDF5 5′-UTR variants, the candidate genomic regions found in most association studies extend from several kilobases upstream (5′) to 100 kb downstream (3′) of GDF5 coding exons (Supplementary Fig. 1) . To better characterize the overall regulatory structure of GDF5, we surveyed upstream and downstream regions of the human and orthologous mouse loci by using transgenic reporter assays and functional rescue experiments in vivo. We found that a large region 3′ of GDF5 is required for both normal joint development and bone length. Interestingly, the selection signatures found in humans were centered on a growth enhancer that we identified in the 3′ region, not the 5′ UTR. The selection peak included an ancient genetic variant present in Neandertals, Denisovans, and modern human populations that we found to decrease the activity of the growth enhancer.
Ancient selection for derived alleles at a GDF5 enhancer influencing human growth and osteoarthritis risk Variants in GDF5 are associated with human arthritis and decreased height, but the causal mutations are still unknown. We surveyed the Gdf5 locus for regulatory regions in transgenic mice and fine-mapped separate enhancers controlling expression in joints versus growing ends of long bones. A large downstream regulatory region contains a novel growth enhancer (GROW1), which is required for normal Gdf5 expression at ends of developing bones and for normal bone lengths in vivo. Human GROW1 contains a common base-pair change that decreases enhancer activity and colocalizes with peaks of positive selection in humans. The derived allele is rare in Africa but common in Eurasia and is found in Neandertals and Denisovans. Our results suggest that an ancient regulatory variant in GROW1 has been repeatedly selected in northern environments and that past selection on growth phenotypes explains the high frequency of a GDF5 haplotype that also increases arthritis susceptibility in many human populations.
Likewise, deletion of the growth enhancer from mice decreased limb length and Gdf5 expression levels in vivo. We propose that selection on the derived variant in this growth enhancer underlies adaptive evolution of the GDF5 gene in both ancient and modern humans, and has led to the high prevalence of a linked risk haplotype that contributes to common skeletal diseases in many populations.
RESULTS

Regulatory and functional scans of Gdf5
To identify regulatory sequences surrounding the mouse Gdf5 locus, we used a BAC scanning approach 31 . Two BAC clones, each containing functional Gdf5 coding sequences, were modified by insertion of a lacZ reporter into the Gdf5 transcription unit and were used to generate transgenic mouse lines ( Fig. 1) . As we have recently reported 32 , regulatory elements within the upstream BAC, spanning 110 kb upstream to 30 kb downstream of Gdf5 exons, drove lacZ expression predominantly in embryonic proximal limb joints and axial structures, whereas elements in the downstream BAC, including an additional 110 kb downstream of Gdf5, drove expression in proximal and distal limb joints, including strong digit expression. More detailed analysis showed that the downstream BAC also drove additional stripes of lacZ expression in the growing ends of long bones rather than joints ( Fig. 1) . This newly identified expression specifically resided along a lateral margin of the developing chondrocyte growth plate within and subjacent to the perichondrium, a region where the endogenous Gdf5 gene is also expressed ( Fig. 1 and Supplementary Figs. 2  and 3) . Mice with Gdf5-null mutations have decreased limb lengths, and this expression is consistent with the known requirement for GDF5 in control of growth-plate dynamics 17 .
To test whether different regulatory regions are required for different Gdf5 functions, we introduced the BAC transgenes, each carrying functional Gdf5 coding regions, separately into a Gdf5-null background provided by mouse brachypodism (bp) mutations 16 . Mice with bp mutations, compared with their wild-type and heterozygous littermates, have approximately 10% shorter long bones and a 50% decrease in metapodial lengths 15 . The upstream BAC allele did not rescue long-bone growth phenotypes, although it did improve metapodial lengths ( Fig. 2 and Supplementary Fig. 4) . In contrast, the downstream BAC allele completely restored all major long bones and metapodial lengths to control lengths ( Fig. 2 and Supplementary  Fig. 4) . Therefore, key functional cis-regulatory sequences controlling limb growth reside at least 30 kb downstream of Gdf5.
Identification of a growth-collar enhancer
To further delineate downstream regulatory sequences, we tested whether smaller human or mouse clones drove consistent lacZ expression in transgenic mice. Different human sequences independently controlled expression in limb joints (41 kb) or growth collars (37 kb) ( Fig. 3) . The 41-kb human clone drove expression in multiple joints and contains multiple joint-control elements, as recently described 32 . In contrast, the 37-kb human clone drove expression in growth-collar domains similarly to the downstream BAC ( Fig. 1) . Growth-zone patterns were also found with a smaller ~12-kb mouse sequence identified by a separate scan across the interval (data not shown). Truncation mapping of the orthologous human region identified a 2.54-kb enhancer ( Fig. 3 and Supplementary Fig. 5 ), which we denoted GROW1 (for GROWTH 1). GROW1 has a chromatin signature typical of enhancers in developing mouse limbs and human chondrocytes (Supplementary Note). Two regions of evolutionary conservation were seen within GROW1: one conserved through amniotes (GROW1A) and one conserved through placental mammals (GROW1B) ( Figs. 3 and 4 and Supplementary Fig. 5 A r t i c l e s tests of each sequence showed that both drove long-bone expression, although the GROW1B pattern was stronger and extended across the growth collar ( Supplementary Fig. 6 ).
Human sequence variants in GROW1
Given the association of GDF5 with height variation and osteoarthritis risk, we queried 1000 Genomes Project data 33 to identify common human SNPs in a 400-kb region surrounding GDF5 (Supplementary Table 1 ). In agreement with the results of other studies 3, 9, 14, 34 , we found no common protein-coding substitutions that could explain the associations ( Supplementary Table 1 ). Instead, we identified many noncoding variants, 19 of which existed within the newly mapped GROW1 enhancer. Of these, 14 were rare (minor allele frequency (MAF) <0.01), 4 were low frequency (MAF <0.03), and 1 was a common variant (MAF >0.05) (Supplementary Table 1 ). The common variant was a G>A substitution (rs4911178) mapping within a highly conserved sequence within GROW1B ( Supplementary  Fig. 5 ). Strikingly, this G is perfectly conserved in placental mammals, whereas A occurs at high frequencies in some human populations ( Figs. 4 and 5a) .
To further examine the functional consequences of this substitution, we recreated the rs4911178 base-pair change in GROW1Bexpression constructs and compared lacZ expression patterns in transgenic embryos (Fig. 4b) . Strikingly, the derived A variant significantly decreased the expression of the growth enhancer in long bones but had no observable effect on facial expression, which served as an internal control.
We also cloned each GROW1B variant upstream of a luciferaseencoding gene and introduced constructs into a human fetal femoral-growth-plate chondrocyte cell line ( Fig. 4c and Supplementary  Fig. 7) . The ancestral GROW1B sequence, compared with control vectors, drove strong luciferase expression, thus confirming its regulatory activity in human cells. The derived GROW1B-enhancer variant drove significantly lower expression than the ancestral variant (0.43-to 0.82-fold change; 500 ng average 0.72-fold change; n = 7 biological replicates; P = 7.7 × 10 −10 ), thus indicating that the human G>A substitution decreases the activity of the GDF5 enhancer in human growth-collar chondrocytes (Supplementary Note).
Distribution of GDF5 variants in modern and ancient humans
We next explored the relationship of the rs4911178 variant to geographic patterns, trait associations, and signatures of selection in humans (Figs. 5 and 6 and Supplementary Note). The lower-activity A variant of GROW1 occurs at high frequencies in Eurasians but at (a) Femoral length is shown as a black line in a hindlimb cartoon with the femur highlighted in gray. The shortened femur of Gdf5-mutant (bp/bp) mice is rescued to control lengths in bp/+; BAC − mice by the presence of the downstream (green) (P = 6.839 × 10 −9 ) but not upstream (yellow) (P = 0.152) Gdf5 BAC constructs (n = 10 skeletal elements per genotype). (b) Digit-length measurements indicated for digit 3 (gray) and metatarsal 3 (MT3) in the hindpaw cartoon. As compared as a ratio to control (bp/+; BAC − ) digit 3 or MT3 lengths, downstream BAC sequences fully restored bp/bp digit 3 lengths (P = 3.793 × 10 −20 ) and MT3 lengths (P = 8.339 × 10 −20 ) to control values, whereas upstream BAC sequences did not rescue bp/bp digit 3 lengths (P = 0.102) and MT3 lengths to control levels, although MT3 lengths did significantly improve (P = 2.327 × 10 −5 ) (n = 10 skeletal elements per genotype). The P values reflect results obtained from unpaired two-tailed t-tests between control bp/bp; BAC − and bp/bp; BAC + samples. In box plots, box limits, upper and lower quartiles; horizontal line, median; whiskers, maximum and minimum values. Figure 3 Fine-mapping of a human GDF5 growth-collar enhancer.
(a) Indicated regions from human (hg19) GDF5 were tested for their ability to drive lacZ expression in developing forelimbs (FL), hindlimbs (HL), and femoral necks and heads. (b) Two fosmid clones, covering 37-kb (dark purple, far left) and 41-kb (light blue, far right) downstream sequences, drive expression at E14.5 in growth plates and joint stripes, respectively (n = 3 embryos per fosmid line). The 37-kb growth-collar lacZ pattern matches that driven by a 2.5-kb sequence (red; GROW1) at E15.5. GROW1 contains at least one smaller 980-bp sequence (yellow, GROW1B) capable of driving expression in growth plates (additional data in supplementary Figs. 5 and 6). The 41-kb sequence drives strong expression in distal joints, for example, knee (k), elbow (e), and digital joints (d), and it contains three previously identified joint enhancers (gray; R3, R4, and R5) 32 . Scale bars, 1 mm (limbs). (c) As compared with the downstream BAC (green, left), the 37-kb growth-region construct (purple) as well as the 2.5-kb (red) and 980-bp (yellow) constructs drive restricted patterns in the proximal femoral neck and shaft, whereas the 41-kb jointregion construct (blue) drives expression confined to the femoral head (n > 5 embryos per construct). An asterisk indicates that the trochanter has not yet fully formed at E14.5. Scale bars, 500 µm (proximal femora).
low frequencies in Africans (Figs. 5a and Supplementary Table 1 ). In Eurasians, the A allele is found near the center of an ~130-kb haplotype that extends from the GDF5 5′ UTR through the downstream region that controls limb length in mice ( Supplementary Figs. 8 and 9 ). SNPs within this region showed high linkage disequilibrium with one another (D′ >0.98; Supplementary Table 2 ), including tight linkage between rs4911178 and other SNPs previously associated with increased osteoarthritis risk (rs143383, r 2 = 0.92) and decreased height in human populations (rs143384, r 2 = 0.88; rs6088813, r 2 = 1; rs725908, r 2 = 1; rs6060373, r 2 = 0.96; rs6088792, r 2 = 0.64; rs6060369, r 2 = 0.96) ( Supplementary Fig. 10 ). Although rs4911178 has not been genotyped in all GWAS, several reports have confirmed that the derived A allele is significantly associated with shorter height (Supplementary Note).
To further examine the evolutionary history of GDF5, we used phased 1000 Genomes data to analyze 1,486 haplotypes spanning the 130-kb linkage block ( Fig. 6a and Supplementary Table 3 ). Removal of low-frequency, putative recombinant haplotypes resulted in 1,091 haplotypes, which we used to construct a maximum-likelihood phylogenetic tree. This tree showed two well-supported clades differing at rs4911178 ( Fig. 6a, Supplementary Fig. 11 and Supplementary Tables 4 and 5). Phylogenetic analyses using all haplotypes yielded similar results ( Supplementary Figs. 12 and 13) . Clade A, consisting exclusively of haplotypes containing the ancestral allele at rs4911178 (398/398), showed marked diversity within and between continents and was the most frequent haplogroup in Africans (145/202; 71.8%). In contrast, clade B consisted of many closely related haplotypes that all possessed the lower-activity derived growth variant at rs4911178 (693/693). This clade showed less sequence diversity and was the predominant haplogroup in Eurasians (i.e., 636/889; 71.5%) ( Supplementary Table 4 ).
A subgroup of haplotypes within the B clade, which we denote B*, was particularly common in Eurasians but was also found at low levels in Kenya (1/202; 0.5% African haplotypes). Analysis of this African individual with Ancestry Informative Markers showed exceptionally low to no detectable evidence of admixture with Europeans 35, 36 (data not shown). Additional Africans (Luhyan and Yoruban) with B* haplotypes were present in the full data set, including low-frequency haplotypes (n = 5 haplotypes) ( Supplementary Figs. 12  and 13) . Interestingly, other Luhyans and Yorubans had haplotypes showing many but not all of the derived SNPs characteristic of B* (Fig. 6a) . These haplotypes were candidate protohaplotypes that may have given rise to the B* haplotype. 
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A r t i c l e s
The high differentiation of GDF5-allele frequencies among populations, as well as the prevalence, size, and low sequence diversity of the B* haplotype in non-Africans, all suggested that B* has been subject to positive selection in Eurasians [11] [12] [13] [14] basis of positive selection 37 . When applied to GDF5, CMS showed a selection peak far downstream of GDF5 coding exons, in the region where we mapped GROW1B ( Fig. 5 and Supplementary Fig. 14) .
Notably, rs4911178 was one of the top three highest-scoring SNPs in the entire 130-kb region. The two other top-scoring SNPs resided in sequences that did not show reproducible enhancer activity in transgenic mice ( Supplementary Fig. 5 and data not shown). Our findings thus suggested that the noncoding change at rs4911178 is the most likely molecular basis for the recent strong selection of GDF5 in non-Africans. Whereas modern Eurasian populations arose from 'out-of-Africa' migrations beginning 130-50 thousand years ago (ka), Neandertals and Denisovans descended from an older migration out of Africa that occurred more than 600 ka. We analyzed Neandertal 38, 39 and Denisovan 40 sequences to reconstruct GDF5 variants present in extinct hominins ( Supplementary Table 3 ). Like many Eurasians, Neandertals and Denisovans show the lower-activity A allele of GROW1B rather than the ancestral G allele, which is highly conserved in other mammals ( Supplementary Table 3 ). Phylogenetic analysis indicted that Neandertal and Denisovan haplotypes cluster within clade B with haplotypes present in Yorubans and Luhyans of Africa, in agreement with sequence-divergence comparisons ( Fig. 6a and Supplementary Table 6 ). Notably, this clade B subgroup is outside the B* cluster that is prevalent in Eurasians, and it does not share the same derived-SNP changes in the GDF5 5′ UTR (for example, rs143384) that have been identified in osteoarthritis association studies. These data suggested that an ancient low-growth variant was present in the human lineage before the last common ancestor of Neandertals, Denisovans and modern humans, and has become the predominant GDF5 variant in both archaic and modern Eurasians.
Functional consequences of GROW1 inactivation
To further examine the phenotypic consequences of changes in the Gdf5 growth enhancer, we used CRISPR-Cas9 editing 41 to delete the GROW1 enhancer from the mouse locus (Supplementary Note). The GROW1-deletion mice lacked a 1.8-kb region, including the mouse ortholog of the rs4911178 site and highly conserved surrounding sequence. Like other mammals, all sequenced wild-type laboratory strains of mice carry a G at the rs4911178 position 42 , similarly to the human ancestral sequence common in Africans. GROW1-deletion mice were viable, fertile, and born in expected Mendelian ratios (Supplementary Note). To identify possible effects of enhancer loss on gene regulation, we generated F 1 hybrid mice heterozygous for both GROW1-deletion and control alleles, and compared the levels of expression of surrounding genes in RNA samples prepared from the growing ends of long bones. Loss of GROW1 significantly decreased the expression of the linked Gdf5 allele but not the linked upstream Cep250 allele or downstream Uqcc1 allele (deletion-allele Gdf5 expression 85 ± 1.48% of control-allele expression, P = 0.02857; deletion-allele Cep250 expression 108 ± 1.78% of control-allele expression, P = 0.2; deletion-allele Uqcc1 expression 88 ± 1.29% of control-allele expression, P = 0.6286; permutation tests; n = 4 biological replicates; Online Methods). These results confirmed that GROW1 is a cis-acting regulatory enhancer required for normal levels of Gdf5 expression at ends of bones.
To test for additional phenotypic consequences of the GROW1 deletion, we analyzed bones of GROW1 −/− and control mice with microcomputerized tomography (µCT) (Fig. 7) . The overall lengths of the femoral neck, femur, and tibia were shorter by ~7.5% (P = 0.007), 2.5% (P = 0.02), and 2% (P = 0.01), respectively, in mutant animals. GROW1 is thus required for normal long-bone growth, and it controls phenotypes that may contribute to both height variation and fracture risk in humans (discussed below).
DISCUSSION
Previously, the most studied functional SNPs in the human GDF5 gene have been rs143383 and rs143884 in the 5′ UTR. Changes at these positions decrease gene expression in cultured cells 3 and have been proposed to be the likely basis of the association with osteoarthritis and height in humans 9, 14 . Because they are located within the mature GDF5 transcript, changes in the 5′ UTR SNPs would probably affect most GDF5 functions. In contrast, our results showed that GDF5 is controlled by a distributed set of regulatory elements that allow for separate regulation of joints and the growing ends of bones ( Figs. 1 and 3) . The P values reflect results obtained from unpaired two-tailed t-tests; n = 12 mice per genotype. Box plots are as in Figure 2 .
A r t i c l e s Several different enhancers are required to drive GDF5 expression in different joints in the skeleton 32 . In addition, the 3′ region also contains the GROW1 enhancer characterized here, which is expressed in the growing ends of long bones, rather than joints between bones (Fig. 3) .
BAC rescue experiments showed that the large 3′ region, containing GROW1, is required for restoration of normal bone lengths in Gdf5 mutants ( Fig. 2 and Supplementary Fig. 4) . Targeted deletion of the GROW1 enhancer also decreases Gdf5 expression and the lengths of long bones in mice, thus confirming that this enhancer functions as a growth-controlling sequence in vivo (Fig. 7) . Interestingly, the orthologous GROW1 sequence in humans contains a common derived SNP (rs4911178) at an otherwise highly conserved position. This change alters a predicted binding site for PITX1, a quintessential regulator of hindlimb growth and patterning in many animals 43 (Supplementary Fig. 15 and Supplementary  Table 7 ). Experimental assays showed that the derived sequence change decreased PITX1 binding interactions in vitro ( Supplementary  Fig. 15 and Supplementary Table 7 ) and decreased GROW1 enhancer activity in both transgenic mice and human growth-plate chondrocytes ( Fig. 4) . We therefore propose that rs4911178 is a causal variant contributing to height variation in humans.
Interestingly, haplotypes containing the derived GROW1 variant show clear evidence of positive selection in Eurasians [11] [12] [13] [14] . Most recently, the CMS measure 37 has narrowed the region of positive selection, and rs4911178 was found to be one of the SNPs most likely to be responsible for positive selection at GDF5 (Fig. 5) . More than 90% of adaptive regions narrowed by CMS scores map to noncoding regulatory regions of genes 37 , though most causal regulatory variants are still unknown. Our results add an interesting new example of a human growth-regulatory variant that has been positively selected in modern Eurasians. In contrast to the few previously known regulatory changes controlling lactose tolerance 44 , eye color 45 , or hair color 46 , we found the same regulatory change in both archaic and modern Eurasians, thus suggesting a long-standing role of GDF5 in modifying human growth and morphology.
Because regulatory mutations typically alter only a subset of normal gene functions, finding signatures of positive selection centered on a particular enhancer can provide useful clues about the likely biological basis of past selection. GDF5 clearly functions in bone growth as well as joint, tendon, and ligament formation, on the basis of multiple alterations in GDF5 coding mutants [15] [16] [17] [18] . In contrast, the selected rs4911178 variant occurs in a noncoding growth-collar enhancer, thus suggesting that specific changes in bone growth rather than joint, tendon, or ligament formation, have been the biological basis of positive selection in humans.
The possible selective advantage of decreased bone growth in Eurasians is still unknown but may include positive assortative mating, sexual selection, energetic control 14 , thermoregulation 47, 48 , or decreased hip-fracture risk 10 . Limb proportions in many endothermic animals follow a classic geographic pattern called Allen's rule, in which species at higher, colder latitudes evolve shorter distal appendages than do closely related species at lower, warmer latitudes 47 . Shorter appendages conserve body heat and lessen the risk of frostbite in extremities in colder environments 47 . Many studies have indicated that cold adaptation has also influenced limb proportions in both modern humans and Neandertals 49, 50 . Mouse Gdf5 mutations are known to disproportionately affect limb and foot length while maintaining the size of the axial skeleton 15, 16 . Similarly, in humans, the common GDF5 haplotype affects standing height but not sitting/trunk height 28 and is also associated with smaller foot size 51 . The prominent effects of the Gdf5 gene on limb growth, and the strong signatures of selection seen over GROW1 in Eurasians, suggest that regulatory changes in this gene may have contributed to classic Allen's rule patterning of limb proportions in humans. We note, however, that derived GDF5 allele frequencies do not show simple latitudinal clines in extant modern populations (Fig. 5) , and other factors are likely to contribute.
Our mouse knockout studies showed that GROW1 has a significant effect on the length of the femoral neck in addition to overall bone length ( Fig. 7) . Femoral-neck length is a key component of hip-axis length, and longer hip-axis lengths are associated with increased hip-fracture rates in humans 52 . The derived allele at the GROW1 enhancer may explain the decreased femoral-neck length and decreased fracture risk previously seen in human GDF5 association studies 10 , and it provides another possible selective advantage in humans migrating to particular environments. Strikingly, the same GROW1B mutation is found in Neandertals, Denisovans, and modern Eurasians. Similar mutations in different populations can arise through independent mutations occurring at the same DNA position, introgression of alleles from one population to another, or independent selection of an ancestral variant already present in the common ancestor of different lineages (Fig. 6b) . For GDF5, independent mutations can be effectively ruled out because many flanking SNPs also show identical changes across a larger linked region, thus indicating a shared haplotype rather than a recurrent mutation at rs4911178. Interestingly, the shared haplotype does not include rs143383 and rs143384 in the GDF5 5′UTR, again highlighting the importance of the 3′ flanking region, and not the 5′ UTR, in the biological functions probably selected at northern latitudes in archaic and modern humans.
Introgression of multiple genomic regions from Neandertals and Denisovans to modern humans is strongly supported by recent studies [38] [39] [40] [53] [54] [55] . However, independent selection of ancestral standing variants can provide an alternative mechanism for allele sharing. In this scenario, ancient variants are already present in a common ancestral population, and the same preexisting variants are independently selected in subsequent lineages. Our sequence analysis of the GDF5 locus suggested that haplotype sharing by archaic and modern humans has most probably arisen through this mechanism. Both A and B haplotype clades are present in modern Africans, including individuals with little evidence of recent admixture. The Neandertal and Denisovan GDF5 haplotype group are within the B clade but represent a long branch within this group, with multiple sequence differences that distinguish the B haplotypes in archaic humans from the B* haplotypes common in modern humans (Fig. 6) . Previously studied cases of introgression from Neandertals to modern humans typically show few base-pair differences between the Neandertal and modern alleles (for example, zero differences for several Neandertal HLA class I alleles) 53 . In contrast, we found a 0.04% divergence between the Neandertal B and modern human B* haplotypes, a result consistent with an extended period of sequence divergence within the B haplogroup ( Supplementary Table 6 ). In addition, the closest nucleotide similarities between Neandertals and Denisovans and modern humans are found in Africa rather than Eurasia, a geographic pattern opposite from that which would be expected if archaic alleles had introgressed into modern populations migrating to northern latitudes. The high frequency of GDF5 B* haplotypes in modern Eurasians and the occurrence of a long-branch B haplotype in Neandertals and Denisovans thus most probably represent separate selection events, each of which relied on ancient genetic variation that was present in Africa but occurred during separate out-of-Africa migrations (Fig. 6c) .
An important consequence of positive selection on the GDF5 locus is that the B* haplotype is now present in billions of people worldwide.
The presence of this haplotype has notable human health implications, because the selected B* haplotype is associated with an increase in osteoarthritis by approximately 1.2-to 1.8-fold, thus representing one of the largest and most replicated genetic associations found for this prevalent form of human joint disease [2] [3] [4] . Although past positive selection for a disease-causing haplotype may seem paradoxical, osteoarthritis typically develops at postreproductive ages. Because evolutionary fitness requires successful reproduction, alleles that confer benefits at young or reproductive ages may be positively selected in populations, even if they have some deleterious consequences in postreproductive ages 56 .
The particular variants within B* haplotypes that cause increased osteoarthritis susceptibility remain unclear. The 5′-UTR rs143383 variant decreases reporter-gene expression in cultured cells 3 and is also associated with lower expression of linked genes in patient articular cartilage 24 . However, the B* haplotype extends over an ~130-kb region that also includes a large and distributed system of regulatory enhancers required for normal expression and function of GDF5 in both joints 32 and growing bones (Fig. 6a) . Genetic variants throughout this haplotype travel in linkage disequilibrium with the selected GROW1 variant rs4911178 and may contribute to changes in osteoarthritis susceptibility. Interestingly, previous studies have suggested that the risk of GDF5-associated arthritis differs in hip, knee, wrist, and finger joints 4 . Some of this anatomical specificity may be related to genetic changes in different joint-specific enhancers, a possibility made more likely by the multiple GDF5 control regions regulating expression in different joints in the proximal and distal regions of the developing limb 32 . Future studies can focus on testing additional human sequence variants within these proximal and distal joint enhancers that may contribute to the very widespread health and morphological effects of the GDF5 locus in modern populations.
ONLINE METHODS
BAC, fosmid, and Hsp68
LacZ plasmid constructs. The 140-kb upstream BAC (306G24) and 200-kb downstream BAC (RP23-316K12), spanning the Gdf5 region, were isolated from mouse libraries and modified by insertion of an internal ribosome-entry site-β-galactosidase reporter cassette (pIRES-B-Geo) in the 3′ UTR of the last exon of Gdf5 (ref. 32) . The size and orientation of the BAC inserts, as well as the sequence of the intact Gdf5 coding exons and targeted 3′-UTR regions, were verified with restriction mapping, pulsed-field gel electrophoresis, Southern blotting, and Sanger sequencing.
Two fosmids, ABC8-2134240-H3 and ABC12-46947700-I24, generated by the Human Genome Structural Variation Project 58 , were chosen on the basis of their overlap with conserved noncoding regions downstream of the upstream BAC ( Supplementary Table 8 ). Fosmid ABC8-2134240-H3, ~37 kb in size, has an ancestral human haplotype, as determined by sequencing, and comes from a Yoruban individual. ABC12-46947700-I24, ~41 kb in size, also has an ancestral haplotype but comes from a CEPH individual heterozygous at this locus. Each fosmid bacterial stab was streaked out on chloramphenicol plates, and individual colonies were picked and grown in LB plus chloramphenicol. After purification with Nucleobond Xtra Maxi Plus kits (Macherey-Nagel, 740416.10), each fosmid was linearized with the NotI restriction enzyme (New England Biolabs, R0189L), purified via three rounds of microinjection buffer exchange with Centriprep-30 concentrators (Amicon, 4306), and run on a CHEF gel overnight. Successfully digested clones were then SNP-and end-sequenceverified, and passed through Centrex MF-15 filters (Schleicher and Schuell, 10467004). Finally, each prepared fosmid was co-injected and co-integrated with a NotI-linearized Hsp68 basal promoter-lacZ reporter vector.
Evolutionarily conserved noncoding regions tested for enhancer activity were either PCR-amplified with primers containing appropriate linker sites from C57BL/6 mouse genomic or human fosmid DNA, or synthesized by GenScript. Each individual region was cloned into a modified (described below) or unmodified p5′-NotI-Hsp68-lacZ expression vector containing a minimal heat-shock promoter and a lacZ cassette. Supplementary Table 8 lists all the constructs used in this study, along with their primers and source DNA. For concatenated constructs, primers containing SfiI linker sequences were used. Their PCR products were briefly ligated to form tandem copies before cloning into a modified p5′-NotI-Hsp68-lacZ vector containing a SfiI restriction site that was inserted between two NotI sites upstream of the lacZ cassette. Ligated DNA was next transformed into DH10 cells and streaked on LB plates containing ampicillin; single colonies were then picked, PCR screened, sequenced, and grown in the presence of ampicillin with standard Maxi-Prep kits (Qiagen). Finally, successful clones were processed for microinjection as described below.
Transgenic mice. Transgenic mice were generated through pronuclear injections carried out by the Stanford Transgenic Facility or by Taconic/Xenogen Biosciences. All constructs were linearized with NotI and then purified for microinjection as described above. Constructs were next microinjected into derived FVB or C57BL6/CBAF1 oocytes. Founder transgenic embryos were collected at E14.5 or E15.5 and X-gal stained. For each transgene, multiple embryos derived from independent injections were compared for their expression patterns, and only reproducible patterns were counted as significant. Stable transgenic mouse lines were also generated for both BAC clones (n = 3 for upstream BAC; n = 5 for downstream BAC). For each stable line, timed matings were established, and the resulting progeny were X-gal stained. The results were directly compared with results from multiple independent founder transgenic embryos. Multiple stable lines were made for each construct, as previously described 32 . For time-course studies, embryos from stable transgenic lines were collected from E14.5 through E16.5 and at specific postnatal time points up to 6 months. All mouse procedures in this and other sections were done in accordance with protocols approved by the Stanford University and Harvard University Institutional Animal Care and Use Committees. X-gal staining. Whole-mount staining for β-galactosidase activity was performed as previously described 32 . Embryos were hemisected and fixed in 4% paraformaldehyde (PFA) (Sigma, 158127) at 4 °C, according to gestational-day guidelines. Fixed embryos were washed three times in wash buffer and stained for 16-24 h in the dark with 1 mg/ml X-gal (Sigma, B4252) in staining buffer at room temperature. For comparisons between ancestral and derived variants, embryos were processed with identical protocols. After staining, embryos were briefly rinsed in wash buffer and postfixed in 4% PFA for 5 h.
In situ hybridization experiments. Antisense and sense digoxigenin-labeled probes for in situ hybridization were generated for Gdf5, Col1a1, and Col2a1 as previously described 32, 59 . To compare Gdf5 lacZ expression, whether driven by the upstream BAC, downstream BAC, or GROW1 regulatory sequence, to endogenous gene expression, E15 lacZ + embryos were harvested, snapfrozen, and embedded in Tissue-Tek OCT compound. Embedded embryos were then serially sectioned with a cryostat. Adjacent sections (n = 3 per experiment) were either stained for lacZ expression with the X-gal staining methods described above or used in standard in situ hybridization protocols as previously described 32 .
BAC rescue experiments and genotyping of progeny. Independent mouse lines carrying either the upstream BAC or the downstream BAC were crossed to animals homozygous for the brachypodism allele (URLs; described below). Multiple different downstream-BAC (n = 5) and upstream-BAC (n = 3) founders were used in the above crosses to control for the integration site of each BAC in the genome. Brachypodism mutations result in frameshifts and premature translational termination in the Gdf5 open reading frame 16 . Animals that were bp/+; Gdf5 − BAC + were then crossed to nontransgenic bp/bp mice. The progeny were genotyped for the lacZ transgene and the brachypodism mutation in separate PCRs, with the primers listed in Supplementary Table 8 . Notably, PCRs for the Gdf5 locus amplified the endogenous Gdf5 rather than the BAC sequences specifically, because the reverse primer was positioned downstream of the IRES-B-Geo insertion at the 3′ UTR of the Gdf5 transgene, thus making amplification inefficient for the BAC. The brachypodism mutation was identified by sequencing around the bp site in the resulting PCR product. Mice that were bp/bp; BAC + , bp/bp; BAC − or bp/+; BAC − were compared as described below.
CRISPR-Cas9 gene targeting of the GROW1 enhancer. Dual sgRNAs surrounding the mouse GROW1 regulatory element were designed with MIT CRISPR Tools (URLs), synthesized by Integrated DNA Technologies, and cloned into the PX458 vector according to a previously described protocol 41 (step 5, part B). The sequences of both sgRNAs are listed in Supplementary  Table 8 . Guide RNAs were initially tested for their ability to induce efficient deletions of the mouse GROW1 enhancer in cultured mouse NIH3T3 cells. NIH3T3 cells were maintained in DMEM (Gibco) supplemented with 10% FCS (Gibco) and 1% penicillin-streptomycin (0.025%), and 0.3 × 10 6 cells were seeded per well of a six-well plate 1 d before transfection. On the day of transfection, cells were incubated for 30 min in 0.5 ml of fresh culture medium, to which we added 0.5 ml of a solution containing 1 µg sgRNA1-PX458 and 1 µg sgRNA2-PX458 in 250 µl Opti-MEM (Invitrogen), and 6 µl Lipofectamine 2000 (Thermo Fisher Scientific) with 250 µl Opti-MEM (Invitrogen). After 2 d of culture at 37 °C, we scanned cells under a fluorescence microscope to verify successful transfection and GFP expression. DNA was then extracted with an E.Z.N.A Tissue DNA Kit, and the GROW1 region was amplified with touchdown PCR and primers surrounding the guide-RNA-design sites (external primers F1 and R1, Supplementary Table 8 ). Amplification products were isolated from 1% agarose gels (E.Z.N.A Gel Extraction Kit) and sequenced (Eton Bioscience) to verify GROW1 deletion.
After confirmation that the sgRNAs worked effectively in vitro, we performed in vitro transcription of sgRNAs by following a previously described method 60 to generate guides useful for DNA microinjection. These sgRNAs along with transfection-ready Cas9 mRNA (CAS500A-1; Systems Biosciences) were provided to the Harvard Genome Modification Facility for microinjection in wild-type C57BL/6J pronuclei. After F 0 founder mice (n = 3) were obtained, we extracted DNA from tail clippings and performed genotyping with the F1 and R1 PCR primers as above. The wild-type amplification product was 2,373 bp, and a subset of founder mice showed a deletion band of ~550 bp. Positive F 0 mice were bred to C57BL/6J mice to transmit the mutations. F 1 progeny from a single stable line were then intercrossed to generate F 2 progeny with wild-type, heterozygous, or homozygous GROW1 genotypes, database (URLs), which is based on replicate experimental measurements of in vitro binding interactions between expressed TFs and all possible octameric target oligonucleotides 63, 64 . For the UniPROBE analysis, two 15-bp sequences differing only at rs4911178 (ancestral (ANC) GTCACAGGGATTATA and derived (DER) GTCACAGAGATTATA were analyzed with a score threshold of 0.2 and species of Homo sapiens. This analysis yielded 703 TF predictions for ANC and 390 TF predictions for DER ( Supplementary Table 7 ). For a TF-binding site to be considered decreased or gained, the site was required to exhibit an enrichment score change >0.10, which corresponded to significant changes in Z score (Supplementary Fig. 7) .
Lists of potential upstream regulators exhibiting marked decreases or increases in binding affinity were then screened with expression and phenotypic data to identify those TFs also expressed or functionally required in growth plates. To carry out this analysis, we used data in VisiGene (URLs), Eurexpress (URLs), Genepaint (URLs), and the Mouse Genome Informatics expression and phenotypic databases (URLs). Two factors, PITX1 and HOXD13 met the above criteria. Each had enrichment scores above the recommended UniPROBE threshold of 0.4 for the ANC sequence but dropped below 0.3 for the DER sequence, and this decrease corresponded to a significant change in Z score (Supplementary Fig. 7) . Pitx1 is expressed in hindlimb growth plates and is required for normal development of hindlimb long bones in humans and mice 43 . Hoxd13 is also expressed in growth plates 65 and is required for normal long-bone development 66 . and 500 ng). For each concentration, we compared the mean expression of the ancestral construct to that of the mean expression of the empty-vector construct or derived construct with a two-sample directional Student's t-test. The P values from independent experiments were combined across either five (for the empty-vector-construct comparison) or seven (for the derived-construct comparison) experiments (at each concentration) with Fisher's combined probability test (two-tailed). Box-and-whisker plots ( Fig. 4 and Supplementary  Fig. 7) show the upper and lower quartiles spanning the interquartile range (edges of the box), the median is marked by a horizontal line within each box, and the whiskers show the maximum and minimum values.
For the allele-specific expression analysis, the permutation test, a nonparametric measure, was used to determine significance between the wild-type and heterozygous allelic expression ratio with the {perm} module in R.
Data availability. The data supporting the findings of this study are available from the corresponding author upon reasonable request.
